US-based Genprex has received approval from the Safety Review Committee (SRC) to proceed to the highest dose group of 0.12mg/kg in the Phase I portion of the Acclaim-3 trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) for extensive stage small cell lung cancer (ES-SCLC).

The trial is designed to evaluate the gene therapy, along with Genentech’s Tecentriq (atezolizumab) as maintenance therapy, for ES-SCLC patients.

This latest move comes after the company completed the 0.09mg/kg dose group.

The SRC, consisting of three principal investigators, observed no dose-limiting toxicities in the current group and recommended the progression to the next dose level. The first patient in this portion of the trial experienced a partial remission, indicating the therapy's potential clinical benefit.

Genprex president and CEO Ryan Confer said: “We believe the SRC’s recommendation to advance to the highest dose group of the Phase I portion of the trial is another clinical validation for our REQORSA development programme.

“We are proud of the achievements so far in the Phase I portion of the trial, which has demonstrated a favourable safety profile for REQORSA in the first trial to use REQORSA for SCLC patients. We look forward to continuing to treat these patients while we work toward bringing new therapies to lung cancer patients with unmet medical need.”

The combination of REQORSA and Tecentriq has received fast-track designation for the treatment of the Acclaim-3 patient population. REQORSA received orphan drug designation to treat SCLC.

The primary objective of the Phase I portion is to establish the maximum tolerated dose or the recommended Phase II dose.

Following the completion of the Phase I stage, the trial will proceed to Phase II, enrolling 50 patients across ten to 15 US sites.

The primary endpoint for Phase II is to assess the 18-week progression-free survival rate. A futility analysis is planned after the 25th patient reaches 18 weeks of follow-up. The trial's Phase I enrolment is expected to conclude, with Phase II commencing in the second half of 2024.

"Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

 

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.